Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Testosterone propionate
Drug ID BADD_D02173
Description Testosterone propionate is a slower-releasing anabolic steroid with a short half-life. It is a synthetic androstane steroid derivative of testosterone in the form of 17β propionate ester of testosterone.[T83] Testosterone propionate was developed initially by Watson labs, and FDA approved on February 5, 1974. Currently, this drug has been discontinued in humans, but the vet application is still available as an OTC.[L1160]
Indications and Usage Testosterone propionate is used in veterinary practice in heifers in order to stimulate maximal growth.[L1160]
Marketing Status approved; investigational; vet_approved; withdrawn
ATC Code Not Available
DrugBank ID DB01420
KEGG ID D00959
MeSH ID D043343
PubChem ID 5995
TTD Drug ID Not Available
NDC Product Code 62991-1412; 38779-0165; 43647-789; 64025-0019; 22552-0015; 49452-0011; 51927-1029; 48087-0134; 51927-0246; 60870-0253; 0009-5123; 30007-833; 52128-172; 51552-0030
UNII WI93Z9138A
Synonyms Testosterone Propionate | Testosteron Propionat Eifelfango | Eifelfango, Testosteron Propionat | Virormone | Agovirin
Chemical Information
Molecular Formula C22H32O3
CAS Registry Number 57-85-2
SMILES CCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Aggression19.05.01.001--Not Available
Alopecia23.02.02.001--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Anger19.04.02.001--Not Available
Anxiety19.06.02.002--
Application site erythema23.03.06.005; 12.07.01.001; 08.02.01.001--Not Available
Application site pain12.07.01.004; 08.02.01.004--Not Available
Application site rash23.03.13.008; 12.07.01.016; 08.02.01.016--Not Available
Arthralgia15.01.02.001--
Asthenia08.01.01.001--Not Available
Azoospermia21.03.03.001--
Blood testosterone decreased13.10.05.004--Not Available
Breast pain21.05.05.003--
Coagulopathy01.01.02.001--Not Available
Confusional state17.02.03.005; 19.13.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dyspnoea02.11.05.003; 22.02.01.004--
Dysuria20.02.02.002--
Endocrine disorder05.09.01.001--Not Available
Epididymitis11.01.19.005; 21.09.02.001--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Gamma-glutamyltransferase increased13.03.04.024--
Gastrointestinal disorder07.11.01.001--Not Available
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages